Finalized Dutch conditional reimbursement system imminent
This article was originally published in SRA
Executive Summary
Formal criteria for what a Dutch conditional reimbursement system will finally look like are due to emerge at the end of the year, Nefarma, the Dutch pharmaceutical industry association says. However, delays in having a finalized system in place could be advantageous to companies with products that are at higher risk of losing reimbursement, said the association.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.